Verastem Inc. | Mutual Funds
Mutual Funds that own Verastem Inc.
Fidelity Select Biotechnology Portfolio
3,101,997
4.22%
0
0.34%
07/31/2018
Vanguard Total Stock Market Index Fund
1,540,076
2.09%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,106,241
1.5%
-591
0.02%
09/06/2018
Vanguard Extended Market Index Fund
904,913
1.23%
211,800
0.01%
07/31/2018
874,857
1.19%
148,359
8.97%
06/30/2018
Fidelity Advisor Biotechnology Fund
636,057
0.86%
-320,043
0.22%
07/31/2018
iShares Russell 2000 Growth ETF
501,296
0.68%
0
0.04%
09/06/2018
PowerShares DWA Healthcare Momentum Portfolio
466,664
0.63%
22,221
1.51%
09/05/2018
Fidelity Spartan Extended Market Index Fund
310,015
0.42%
59,116
0.01%
07/31/2018
PowerShares DWA Small Cap Momentum Portfolio
192,292
0.26%
0
0.42%
09/05/2018
| Address |
117 Kendrick Street
Needham Massachusetts 02494
United States
|
|
Employees
|
- |
| Website |
http://www.verastem.com |
| Updated |
07/08/2019 |
| Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. |
